以硼替佐米和糖皮质激素为基础的联合方案治疗6例复发/难治免疫性血栓性血小板减少性紫癜
纳入6例复发/难治免疫性血栓性血小板减少性紫癜(iTTP)患者,采用糖皮质激素联合2个疗程硼替佐米为基础方案治疗,观察临床缓解、ADAMTS13活性/抑制物及不良反应。6例均获临床缓解,ADAMTS13活性恢复正常、抑制物转阴;中位随访26(9~41)个月,5例持续缓解、1例16个月后复发。
要点
- 6例复发/难治iTTP患者经糖皮质激素联合2个疗程硼替佐米为基础方案治疗后均获临床缓解。
- 治疗后ADAMTS13活性均恢复正常,ADAMTS13抑制物均转为阴性。
- 不良反应包括血小板减少、末梢神经炎和腹痛,最终均恢复正常。
核心结论
- 以硼替佐米联合糖皮质激素为基础的联合治疗对复发/难治iTTP具有较满意的疗效且不良反应可控。
研究设计与样本
- 纳入6例复发/难治iTTP患者,采用糖皮质激素联合2个疗程硼替佐米为基础的方案治疗,观察临床缓解、ADAMTS13活性/抑制物变化及治疗相关不良反应。
主要发现
- 6例中男2例、女4例,中位年龄21.5(18~68)岁;难治性1例,复发性5例。
- 糖皮质激素参照泼尼松1 mg·kg(-1)·d(-1)等效剂量给药,获得临床缓解后逐渐减量。
- 硼替佐米1.3 mg/m(2)皮下注射,第1、4、8、11天,28 d一个疗程,共2个疗程。
- 6例均获得临床缓解,ADAMTS13活性恢复正常,ADAMTS13抑制物转为阴性。
- 中位随访26(9~41)个月,5例持续缓解,1例患者16个月后复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe the efficacy and adverse reactions of a combination therapy regimen based on bortezomib and glucocorticoids in recurrent/refractory immune thrombocytopenic purpura (iTTP) . Methods: Six patients with recurrent/refractory TTP were included and treated with a glucocorticoid and two courses of bortezomib-based regimen. The clinical remission status of patients, changes in ADAMTS13 activity/ADAMTS13 inhibitor, and the occurrence of treatment-related adverse reactions were observed. Results: Of the 6 patients, 2 were males and 4 were females, with a median age of 21.5 (18-68) years. Refractory TTP was found in 1 case and recurrent TTP in 5 cases. Glucocorticoids were administered with reference to prednisone at 1 mg·kg(-1)·d(-1), and gradually reduced in dosage after achieving clinical remission. Bortezomib is subcutaneously administered at 1.3 mg/m(2) on days 1, 4, 8, and 11 with a 28-day treatment course consisting of 2 courses. Six patients achieved clinical remission after receiving bortezomib as the main treatment. ADMATS13 activity returned to normal in all patients with TTP after treatment, and the ADAMTS13 inhibitor turned negative. Thrombocytopenia is the most common adverse reaction after treatment, with other adverse reactions, including peripheral neuritis and abdominal pain, but ultimately all patients returned to normal. In a median follow-up of 26 (9-41) months, 5 patients maintained sustained remission, and 1 patient relapsed after 16 months of bortezomib treatment. Conclusion: Combination therapy of bortezomib and glucocorticoids has a satisfactory therapeutic effect and controllable adverse reactions for recurrent/refractory iTTP. 目的: 观察硼替佐米联合糖皮质激素为基础的联合治疗方案在复发/难治免疫性血栓性血小板减少性紫癜(iTTP)中的疗效和不良反应。 方法: 纳入6例复发/难治iTTP患者,采用硼替佐米联合糖皮质激素为基础的联合方案治疗。观察患者临床缓解情况、ADAMTS13活性/ADAMTS13抑制物变化及治疗相关不良反应的发生情况。 结果: 6例iTTP患者中,男2例,女4例,中位年龄为21.5(18~68)岁,难治性1例,复发性5例。糖皮质激素参照泼尼松1 mg·kg(-1)·d(-1)等效剂量给药,获得临床缓解后逐渐减量;硼替佐米1.3 mg/m(2)皮下注射,第1、4、8、11天,28 d一个疗程,共2个疗程。6例iTTP患者均获得临床缓解,ADMATS13活性恢复正常,ADAMTS13抑制物转为阴性。不良反应包括血小板减少、末梢神经炎和腹痛,均恢复正常。中位随访26(9~41)个月,5例患者持续缓解,1例患者16个月后复发。 结论: 以硼替佐米硼替佐米联合糖皮质激素为基础的联合治疗对复发/难治iTTP具有较满意的疗效且不良反应可控。.
引用
- Yin J, Tian H, Kong DQ, et al. [A combined regimen based on bortezomib and glucocorticoids for 6 patients with recurrent/refractory immune thrombotic thrombocytopenic purpura]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37550192. doi:10.3760/cma.j.issn.0253-2727.2023.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。